The added value of (1,3)-β-D-glucan for the diagnosis of Invasive Candidiasis in ICU patients : a prospective cohort study
© 2023. The Author(s)..
PURPOSE: Beta-D-Glucan (BDG) testing has been suggested to support the diagnosis of candidemia and invasive candidiasis. The actual benefit in critically ill high-risk patients in intensive care units (ICU) has not been verified so far.
METHODS: In ICU patients receiving empirical echinocandin treatment for suspected invasive candidiasis (IC), serial BDG testing using the Fujifilm Wako Beta-Glucan Test was performed, starting on the first day of echinocandin administration and every 24-48 h afterwards. Diagnostic accuracy was determined for single testing and serial testing strategies using a range of cut-off values. In addition, we compared the added value of these testing strategies when their results were introduced as additional predictors into a multivariable logistic regression model controlling for established risk factors of IC.
RESULTS: A total of 174 ICU patients, forty-six of which (25.7%) classified as cases of IC, were included in our study. Initial BDG testing showed moderate sensitivity (74%, 95%CI 59-86%) and poor specificity (45%, 95% CI 36-54%) for IC which could hardly be improved by follow-up testing. While raw BDG values or test results obtained with very high thresholds improved the predictive performance of our multivariable logistic regression model for IC, neither single nor serial testing with the manufacturer-proposed low-level cut-off showed substantial benefit.
CONCLUSIONS: In our study of critically ill intensive care patients at high risk for candidemia or invasive candidiasis, diagnostic accuracy of BDG testing was insufficient to inform treatment decisions. Improved classification was only achieved for cases with very high BDG values.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Infection - 52(2024), 1 vom: 15. Feb., Seite 73-81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Christner, Martin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
(1,3)-β-D-glucan |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 07.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s15010-023-02053-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358239753 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358239753 | ||
| 003 | DE-627 | ||
| 005 | 20240307231922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-023-02053-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM358239753 | ||
| 035 | |a (NLM)37322388 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Christner, Martin |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The added value of (1,3)-β-D-glucan for the diagnosis of Invasive Candidiasis in ICU patients |b a prospective cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a PURPOSE: Beta-D-Glucan (BDG) testing has been suggested to support the diagnosis of candidemia and invasive candidiasis. The actual benefit in critically ill high-risk patients in intensive care units (ICU) has not been verified so far | ||
| 520 | |a METHODS: In ICU patients receiving empirical echinocandin treatment for suspected invasive candidiasis (IC), serial BDG testing using the Fujifilm Wako Beta-Glucan Test was performed, starting on the first day of echinocandin administration and every 24-48 h afterwards. Diagnostic accuracy was determined for single testing and serial testing strategies using a range of cut-off values. In addition, we compared the added value of these testing strategies when their results were introduced as additional predictors into a multivariable logistic regression model controlling for established risk factors of IC | ||
| 520 | |a RESULTS: A total of 174 ICU patients, forty-six of which (25.7%) classified as cases of IC, were included in our study. Initial BDG testing showed moderate sensitivity (74%, 95%CI 59-86%) and poor specificity (45%, 95% CI 36-54%) for IC which could hardly be improved by follow-up testing. While raw BDG values or test results obtained with very high thresholds improved the predictive performance of our multivariable logistic regression model for IC, neither single nor serial testing with the manufacturer-proposed low-level cut-off showed substantial benefit | ||
| 520 | |a CONCLUSIONS: In our study of critically ill intensive care patients at high risk for candidemia or invasive candidiasis, diagnostic accuracy of BDG testing was insufficient to inform treatment decisions. Improved classification was only achieved for cases with very high BDG values | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (1,3)-β-D-glucan | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Intensive care unit | |
| 650 | 4 | |a Invasive Candidiasis | |
| 650 | 7 | |a polysaccharide-K |2 NLM | |
| 650 | 7 | |a 3X48A86C8K |2 NLM | |
| 650 | 7 | |a Glucans |2 NLM | |
| 650 | 7 | |a Echinocandins |2 NLM | |
| 650 | 7 | |a beta-Glucans |2 NLM | |
| 650 | 7 | |a Proteoglycans |2 NLM | |
| 700 | 1 | |a Abdennadher, Beya |e verfasserin |4 aut | |
| 700 | 1 | |a Wichmann, Dominic |e verfasserin |4 aut | |
| 700 | 1 | |a Kluge, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Pepić, Amra |e verfasserin |4 aut | |
| 700 | 1 | |a Aepfelbacher, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Rohde, Holger |e verfasserin |4 aut | |
| 700 | 1 | |a Olearo, Flaminia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d 1973 |g 52(2024), 1 vom: 15. Feb., Seite 73-81 |w (DE-627)NLM00001740X |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2024 |g number:1 |g day:15 |g month:02 |g pages:73-81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s15010-023-02053-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2024 |e 1 |b 15 |c 02 |h 73-81 | ||